Intellia Therapeutics (NTLA) EBT Margin Growth (5y) (2020 - 2026)
Powered by 
Analysis
Intellia Therapeutics (NTLA) EBT Margin Growth (5y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34,609.00 |
| Mar 31, 2026 | 8,343.00 |
| Dec 31, 2025 | 23,904.00 |
| Sep 30, 2025 | -63,485.00 |
| Jun 30, 2025 | -52,103.00 |
| Mar 31, 2025 | -42,858.00 |
| Dec 31, 2024 | -71,873.00 |
| Sep 30, 2024 | -123,328.00 |
| Jun 30, 2024 | -158,905.00 |
| Mar 31, 2024 | -14,005.00 |
| Dec 31, 2023 | 688,948.00 |
| Sep 30, 2023 | -68,060.00 |
| Jun 30, 2023 | -59,097.00 |
| Mar 31, 2023 | -50,717.00 |
| Dec 31, 2022 | -41,225.00 |
| Sep 30, 2022 | -57,096.00 |
| Jun 30, 2022 | -43,211.00 |
| Mar 31, 2022 | -107,393.00 |
| Dec 31, 2021 | -43,397.00 |
| Sep 30, 2021 | -84,084.00 |